

Healthcare Resource Utilization Among Adults with Schizophrenia and Negative Symptoms: A Real-World Data Study

Nadia Lipunova¹, Joannas Yeow¹, Laila Hadaya¹, Emily OC Palmer¹, Subina Surendran¹, Matthew Sidovar^{2*}, Kristin Gillard²

1. Holmusk Technologies Inc., UK and Singapore, 2. Bristol-Myers Squibb Company, Princeton, NJ

*At the time the analysis was conducted.

Introduction

- Negative symptoms in schizophrenia (NSS), including avolition, anhedonia, and reduced emotional expression¹, affect approximately 60% of individuals and are associated with significant functional impairment²⁻⁴
- Understanding the impact of negative symptoms on healthcare resource utilization in patients with schizophrenia is crucial for healthcare systems to optimize resource allocation and develop targeted interventions

Methods

Study Design and Data Source

- This retrospective cohort study analyzed electronic health records from NeuroBlu Data (V24R5) linked with Inovalon MORE2 Registry® of Closed Claims (MORE2) and the 100% Medicare Fee-for-Service (FFS) databases
- NeuroBlu Data is a de-identified, longitudinal behavioral health real-world database comprising structured and unstructured patient-level records from US mental healthcare providers spanning 1999 to 2024. Inovalon is a real-world database that includes medical and pharmacy closed claims between 2019 and 2024

Study Population

Patients were included if further conditions were met:

- A recorded diagnosis of schizophrenia in NeuroBlu Data
- At least on record the following: a mental status examination (MSE), negative symptoms label extracted via Natural Language Processing (NLP), or Brief Negative Symptoms Assessment (BNSA) within ± 14 days of a diagnosis of schizophrenia
- Aged ≥18 years at the time of the MSE/NLP/BNSA assessment
- A record of payer plan period throughout the 12-month follow-up in Inovalon claims dataset

Exposure

The exposure of interest was NSS. Patients were classified as having evidence of negative symptoms if any of the following conditions were met: (1) BNSA total score ≥9 points, (2) NLP label indicating presence of negative symptoms, or (3) MSE documentation of negative symptoms. All conditions were assessed within a time window of ±14 days around a diagnosis of schizophrenia to ensure clinical relevance of recorded symptoms. If multiple conditions were met, the earliest record by date was selected as the index event

Outcomes

The study outcomes were counts of healthcare visits (inpatient, outpatient, and emergency department) during the 12-month follow-up period, stratified into psychiatry-related and non-psychiatry-related visits. Psychiatry-related visits included those occurring in a psychiatric setting (departments or with psychiatric provider specialties) or having associated psychiatric diagnostic codes, procedures, prescriptions, or clinical measurements. Non-psychiatry-related visits encompassed all other healthcare activity

Study Objective

- To estimate the association between negative symptoms features and the number of psychiatry-related and non-psychiatric inpatient, outpatient, and emergency visits among patients with schizophrenia within a 12-month follow-up

Covariates


Potential confounders, used in both propensity score assessment and regression adjustment, included demographic (age, sex, race, and ethnicity) and clinical characteristics (care setting, psychiatric and medical comorbidities, presence of positive symptoms, cognitive impairment, psychopharmacological treatments, and insurance type)

Statistical Analysis

- Descriptive statistics were calculated for all variables, with continuous variables summarized using medians and interquartile range, and categorical variables summarized using absolute counts and percentages
- Stabilized inverse probability treatment weighing (IPTW) was used to create balanced cohorts between patients with and without negative symptoms. Propensity scores were estimated using logistic regression and included all listed covariates
- Extreme weights below the 1st percentile or above the 99th percentile were trimmed to prevent disproportionate influence of outlier observations
- Covariate balance was assessed using standardized mean differences (SMDs) for continuous variables and raw mean differences (RMDs) for categorical variables, with differences ≤ 0.1 considered adequately balanced
- Negative binomial regression was used to assess the relationship between negative symptoms and HCRU outcomes. Zero-inflated negative binomial regression was applied when data was zero-inflated. Double-robust adjustment was performed by including all propensity score covariates into regression models. Additional covariates, not used in the weighing, were adjusted for in the regression (payer type, LAI prescription at baseline, psychotherapy at baseline, data source) to further control for potential confounding
- Outcome results are presented as incidence rate ratios (IRRs) with 95% confidence intervals, where IRR >1.0 indicates higher service use among patients with negative symptoms, IRR <1.0 indicates lower service use, and IRR = 1.0 indicates no difference compared with patients without negative symptoms

Study Population

The linked claims cohort included 2,616 adults (1,774 (68%) with NSS) (Figure 1). After IPTW, the cohort had an effective sample size (ESS) of 1,676 patients (1,282 (77%) with NSS). The ESS for the weighted analysis is lower than the nominal population size, meaning the propensity score weighted analyses have approximately the same statistical power as an unweighted sample with 1,676 individuals



Descriptive characteristics

Table 1 shows baseline characteristics after applying IPTW. The ESS represents the number of independent observations required by an unweighted sample to obtain the same level of precision achieved after applying IPTW. It is a measure of statistical information rather than a participant count, and therefore subgroup ESS values do not sum to the total

Table 1. Population characteristics after weighing.


Variable	With NSS (ESS = 1,282)	Without NSS (ESS = 394)	SMD/ RMD
Age at baseline (years)	Median [Q1, Q3] 38 [28, 54]	39 [27, 52]	
Sex, n (%)	Female 1051.5 (59.6%)	319.5 (42.8%)	0.02
	Male 650.67 (36.9%)	427.52 (57.2%)	
Race, n (%)	White 879.72 (49.8%)	247.05 (33.1%)	0.03
	Black or African American 110.98 (6.3%)	396.39 (53.1%)	<0.01
	Other Race 124.17 (7%)	48.75 (6.5%)	<0.01
	Unknown 68.15 (3.9%)	54.82 (7.3%)	0.04
Ethnicity, n (%)	Hispanic or Latino 1031.58 (58.4%)	26.92 (3.6%)	<0.01
	Not Hispanic or Latino 665.79 (37.7%)	428.47 (57.4%)	0.01
	Unknown 471.37 (26.7%)	291.62 (39%)	0.01
Clinical setting at index date, n (%)	Inpatient visit 1093.97 (62%)	130.04 (17.4%)	0.09
	Emergency room visit 502.14 (28.4%)	418.43 (56%)	0.06
	Other setting 994.45 (56.3%)	267.64 (35.8%)	0.07
Symptoms, n (%)	Positive symptoms 937.27 (53.1%)	490.47 (65.7%)	0.09
	Cognitive impairment symptoms 1017.62 (57.6%)	345.96 (46.3%)	0.07
	Attention deficit hyperactivity disorder 80.21 (4.5%)	389.04 (52.1%)	0.06
	Bipolar I or II disorder 161.27 (9.1%)	36.85 (4.9%)	<0.01
	Borderline personality disorder 39.25 (2.2%)	77.18 (10.3%)	0.01
	Generalized anxiety disorder 44.97 (2.5%)	13.99 (1.9%)	<0.01
	Major depressive disorder 252.25 (14.3%)	13.7 (1.8%)	0.01
	Obsessive compulsive disorder 17.85 (1%)	88 (11.8%)	0.03
	Posttraumatic stress disorder 137.38 (7.8%)	8.72 (1.2%)	<0.01
	Schizoaffective disorder 329.82 (18.7%)	56.32 (7.5%)	<0.01
Comorbidities and treatment at baseline, n (%)	Substance use disorder (or treatment) 886.57 (50.2%)	112.25 (15%)	0.04
	Cardiovascular disorders (or cardiovascular treatment) 713.32 (40.4%)	341.37 (45.7%)	0.05
	Diabetes mellitus (or hypoglycemic treatment) 261.09 (14.8%)	283.51 (38%)	0.05
	Antidepressants 885.59 (50.2%)	118.88 (15.9%)	0.01
	First generation antipsychotics 611.92 (34.7%)	332.16 (44.5%)	0.06
	Second generation antipsychotics 1083.47 (61.4%)	241.08 (32.3%)	0.02
	Medicaid 54.48 (3.1%)	422 (56.5%)	0.05
	Medicare 100.53 (5.7%)	23.98 (3.2%)	<0.01
	Commercial 1630.63 (92.4%)	53.62 (7.2%)	0.02

IQR, interquartile range; NSS, negative symptoms in schizophrenia; SD, standard deviation; SMD, standard mean difference; RMD, raw mean difference.

Results

Negative symptoms in schizophrenia were associated with higher utilization of crisis-based services

Figure 2. Association between negative symptoms in schizophrenia and healthcare resource utilization (psychiatry-related and non-psychiatry-related). The figure shows incidence rate ratios (IRRs) and 95% confidence intervals.



Discussion

- Healthcare utilization analyses revealed that negative symptoms were associated with substantial increases in emergency and inpatient care utilization. Critically, these increases occurred without corresponding changes in outpatient utilization, suggesting a potential breakdown in preventive care
- These findings may reflect the motivational and volitional deficits inherent to negative symptoms that impair patients' capacity to maintain regular outpatient appointments and engage proactively with healthcare services, leading to clinical deterioration requiring acute intervention. The consistency of this pattern across both psychiatry-related and non-psychiatry-related settings suggests that negative symptoms create barriers to healthcare engagement that transcend specialty boundaries

Limitations

This study has constraints including potential unmeasured confounding, low linkage rate between EHR and claims data that may limit study generalizability, and reliance on multiple routine assessments rather than a single scale (e.g., MSE rather than formal assessments such as Positive and Negative Syndrome Scale (PANSS)).

Conclusions

- NSS were associated with substantially increased crisis-driven HCRU across both psychiatry-related and non-psychiatry-related services
- These findings highlight opportunities for targeted interventions addressing negative symptoms in schizophrenia to potentially improve care coordination, reduce healthcare costs, and enhance patient outcomes

References

- Correll CU, Schooler NR. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. *Neuropsychiatr Dis Treat*. 2020;16:519-53
- Santesteban-Echarri O, et al., Predictors of functional recovery in first-episode psychosis: A systematic review and meta-analysis of longitudinal studies. *Clin Psychol Rev*. 2017. 58: p. 59-75.
- McGurk, S.R., et al., Relationship of cognitive functioning, adaptive life skills, and negative symptom severity in poor-outcome geriatric schizophrenia patients. *The Journal of neuropsychiatry and clinical neurosciences*, 2000. 12(2): p. 257-264.
- Rabinowitz, J., et al., Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. *Schizophrenia Research*, 2012. 137(1): p. 147-150.

Declaration of interests

NL, EOCP, MO, SS, and JY report employment with and equity ownership in KKT Technologies, Pte. Ltd. or its subsidiaries. MS was an employee of Bristol Myers Squibb at the time the analysis was conducted. KG is an employee of Bristol Myers Squibb.

Acknowledgment

This analysis was conducted by Holmusk Technologies, Inc., and supported by Bristol Myers Squibb. Medical writing and editorial assistance were provided by Holmusk Technologies Inc., funded by Bristol Myers Squibb. All authors contributed to and approved the poster.

Scientific Content on Demand

To request a copy of this poster:



Scan QR code via a barcode reader application

QR codes are valid for 30 days after the congress presentation date.